245 related articles for article (PubMed ID: 35340081)
1. Surgical and focal treatment for metastatic renal cell carcinoma: A literature review.
Naito S; Kato T; Tsuchiya N
Int J Urol; 2022 Jun; 29(6):494-501. PubMed ID: 35340081
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
Iisager L; Ahrenfeldt J; Donskov F; Ljungberg B; Bex A; Lund L; Lyskjær I; Fristrup N
BMC Cancer; 2024 Feb; 24(1):260. PubMed ID: 38402173
[TBL] [Abstract][Full Text] [Related]
3. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Tsushima E; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Int J Urol; 2021 Apr; 28(4):369-375. PubMed ID: 33314387
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
5. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
Larcher A; Wallis CJD; Bex A; Blute ML; Ficarra V; Mejean A; Karam JA; Van Poppel H; Pal SK
Eur Urol Oncol; 2019 Jul; 2(4):365-378. PubMed ID: 31109902
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Graham J; Bhindi B; Heng DYC
Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
[TBL] [Abstract][Full Text] [Related]
8. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
Napolitano L; Manfredi C; Cirillo L; Fusco GM; Passaro F; Abate M; La Rocca R; Mastrangelo F; Spirito L; Pandolfo SD; Crocetto F; Arcaniolo D; Barone B
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109725
[TBL] [Abstract][Full Text] [Related]
10. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
[TBL] [Abstract][Full Text] [Related]
11. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
Dariane C; Timsit MO; Méjean A
Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
[TBL] [Abstract][Full Text] [Related]
12. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract][Full Text] [Related]
13. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
14. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
[TBL] [Abstract][Full Text] [Related]
15. Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Zequi SC
Int Braz J Urol; 2020; 46(3):476. PubMed ID: 32167723
[No Abstract] [Full Text] [Related]
16. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
17. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.
Dawsey SJ; Campbell SC; Ornstein MC
Curr Oncol; 2021 May; 28(3):1921-1926. PubMed ID: 34065284
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
20. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
